Skip to main
ZTS

Zoetis (ZTS) Stock Forecast & Price Target

Zoetis (ZTS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 33%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Zoetis demonstrates a positive outlook through significant investments in pet owner relationships, as evidenced by the increase in enrollment in the Zoetis Petcare Rewards program to 2.5 million users, up from 708,000 in 2018, alongside over $120 million allocated towards marketing in 2023. The company's revenue from key products such as Simparica, which generated $356 million in the third quarter, highlights a year-over-year growth of 7%, underscoring its strong market position in the companion animal sector. Additionally, core dermatological products have shown resilience, achieving $469 million in global revenue with a 3% year-over-year increase, further solidifying Zoetis's dominant presence in the animal health market.

Bears say

Zoetis has revised its 2025 revenue guidance downward to a range of $9.400 billion to $9.475 billion, reflecting diminished organic operational growth expectations, which indicates potential difficulties in maintaining growth momentum. The company's pain management segment experienced a significant 11% year-over-year decline due to safety concerns surrounding one of its products, impacting sales in a critical area. Additionally, the company's recent earnings report revealed a troubling stagnation in the U.S. companion animal health segment, attributed to increased competition and a drop in veterinary clinic visits, raising concerns about the sustainability of its revenue foundations.

Zoetis (ZTS) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 33% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zoetis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zoetis (ZTS) Forecast

Analysts have given Zoetis (ZTS) a Buy based on their latest research and market trends.

According to 9 analysts, Zoetis (ZTS) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $166.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $166.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zoetis (ZTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.